Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)

Study objective: to estimate efficiency of atorvastatin therapy in patients with type 2 diabetes mellitus (T2DM), who are the carrier of various genotypes Q192R paraoxonase gene 1 (PON1). 386 T2DM patients, who have not received statin therapy before, and 187 healthy people were examined. All those...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Kim, S. A. Skoryukova, A. A. Bystrova, E. I. Baranova, S. N. Pchelina
Format: Article
Language:Russian
Published: Academician I.P. Pavlov First St. Petersburg State Medical University 2015-03-01
Series:Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
Subjects:
Online Access:https://www.sci-notes.ru/jour/article/view/122
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850026183533527040
author M. V. Kim
S. A. Skoryukova
A. A. Bystrova
E. I. Baranova
S. N. Pchelina
author_facet M. V. Kim
S. A. Skoryukova
A. A. Bystrova
E. I. Baranova
S. N. Pchelina
author_sort M. V. Kim
collection DOAJ
description Study objective: to estimate efficiency of atorvastatin therapy in patients with type 2 diabetes mellitus (T2DM), who are the carrier of various genotypes Q192R paraoxonase gene 1 (PON1). 386 T2DM patients, who have not received statin therapy before, and 187 healthy people were examined. All those examined were exposed to blood lipid profile testing and molecular genetic research. The atorvastatin treatment group included 164 T2DM patients with abnormality of lipids, their blood lipid profile values were assessed before and after 3 months of the therapy. Blood lipid profile values did not differ in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism. Atorvastatin therapy decreased atherogenic lipoprotein levels in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism, but reduction degree in the carriers of different Q192R genotypes differed - in Q192Q bearers it was greater than in the bearers of Q192R genotype of gene PON1 (р = 0,031). Atorvastatin 3-months therapy revealed greater reduction of total cholesterol in the carriers of Q192Q genotype of gene 1 (PON1) than in the carriers of Q192R genotype of gene 1 (PON1).
format Article
id doaj-art-d5a42e8e77eb475aa35fbc12d825f06b
institution DOAJ
issn 1607-4181
2541-8807
language Russian
publishDate 2015-03-01
publisher Academician I.P. Pavlov First St. Petersburg State Medical University
record_format Article
series Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
spelling doaj-art-d5a42e8e77eb475aa35fbc12d825f06b2025-08-20T03:00:37ZrusAcademician I.P. Pavlov First St. Petersburg State Medical UniversityУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова1607-41812541-88072015-03-01221869110.24884/1607-4181-2015-22-1-86-91118Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)M. V. Kim0S. A. Skoryukova1A. A. Bystrova2E. I. Baranova3S. N. Pchelina4Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-Западный федеральный медицинский исследовательский центр Министерства здравоохранения Российской ФедерацииПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-Западный федеральный медицинский исследовательский центр Министерства здравоохранения Российской ФедерацииПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-Западный федеральный медицинский исследовательский центр Министерства здравоохранения Российской ФедерацииПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-Западный федеральный медицинский исследовательский центр Министерства здравоохранения Российской ФедерацииПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Северо-Западный федеральный медицинский исследовательский центр Министерства здравоохранения Российской ФедерацииStudy objective: to estimate efficiency of atorvastatin therapy in patients with type 2 diabetes mellitus (T2DM), who are the carrier of various genotypes Q192R paraoxonase gene 1 (PON1). 386 T2DM patients, who have not received statin therapy before, and 187 healthy people were examined. All those examined were exposed to blood lipid profile testing and molecular genetic research. The atorvastatin treatment group included 164 T2DM patients with abnormality of lipids, their blood lipid profile values were assessed before and after 3 months of the therapy. Blood lipid profile values did not differ in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism. Atorvastatin therapy decreased atherogenic lipoprotein levels in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism, but reduction degree in the carriers of different Q192R genotypes differed - in Q192Q bearers it was greater than in the bearers of Q192R genotype of gene PON1 (р = 0,031). Atorvastatin 3-months therapy revealed greater reduction of total cholesterol in the carriers of Q192Q genotype of gene 1 (PON1) than in the carriers of Q192R genotype of gene 1 (PON1).https://www.sci-notes.ru/jour/article/view/122сахарный диабетдислипидемияген параоксоназы 1аторвастатинdiabetes mellitusdyslipidemiaparaoxonase 1 geneatorvastatin
spellingShingle M. V. Kim
S. A. Skoryukova
A. A. Bystrova
E. I. Baranova
S. N. Pchelina
Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
сахарный диабет
дислипидемия
ген параоксоназы 1
аторвастатин
diabetes mellitus
dyslipidemia
paraoxonase 1 gene
atorvastatin
title Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
title_full Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
title_fullStr Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
title_full_unstemmed Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
title_short Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
title_sort q192r paraoxonase gene 1 pon1 polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus t2dm
topic сахарный диабет
дислипидемия
ген параоксоназы 1
аторвастатин
diabetes mellitus
dyslipidemia
paraoxonase 1 gene
atorvastatin
url https://www.sci-notes.ru/jour/article/view/122
work_keys_str_mv AT mvkim q192rparaoxonasegene1pon1polymorphismandatorvastatintherapyeffectinpatientswithtype2diabetesmellitust2dm
AT saskoryukova q192rparaoxonasegene1pon1polymorphismandatorvastatintherapyeffectinpatientswithtype2diabetesmellitust2dm
AT aabystrova q192rparaoxonasegene1pon1polymorphismandatorvastatintherapyeffectinpatientswithtype2diabetesmellitust2dm
AT eibaranova q192rparaoxonasegene1pon1polymorphismandatorvastatintherapyeffectinpatientswithtype2diabetesmellitust2dm
AT snpchelina q192rparaoxonasegene1pon1polymorphismandatorvastatintherapyeffectinpatientswithtype2diabetesmellitust2dm